The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 3, 2006, Pages 1006-1019

  Hansen, Henrik H ^a   Ebbesen, Christina ^a   Mathiesen, Claus ^a   Weikop, Pia ^a   Rønn, Lars Christian ^a   Waroux, Olivier ^b   Scuvée Moreau, Jacqueline ^b   Seutin, Vincent ^b   Mikkelsen, Jens D ^a  

^a NEUROSEARCH A S   (Denmark)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; 3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; 4 (N ETHYL N PHENYLAMINO) 1,2 DIMETHYL 6 (METHYLAMINO)PYRIMIDINIUM CHLORIDE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 4 PYRIDINYLMETHYL 9(10H) ANTHRACENONE; APAMIN; DOPAMINE; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL STIMULATING AGENT; PROTEIN C FOS; RACLOPRIDE; RETIGABINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG INHIBITION; DRUG MECHANISM; ELECTROPHYSIOLOGY; HYPERPOLARIZATION; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIMBIC SYSTEM; MALE; MESENCEPHALON; MICRODIALYSIS; NERVE EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

ANIMALS; ANTHRACENES; CARBAMATES; DOPAMINE; DOPAMINE ANTAGONISTS; HALOPERIDOL; KCNQ POTASSIUM CHANNELS; MALE; MESENCEPHALON; PHENYLENEDIAMINES; PHOSPHORYLATION; PROTEIN SUBUNITS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

EID: 33747618030     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.106757     Document Type: Article

References (41)

1. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, and Steinlein OK (1998) A potassium channel mutation in neonatal human epilepsy. Science (Wash DC) 279:403-406.
2. Blackburn-Munro G, Dalby-Brown W, Mirza NR, Mikkelsen JD, and Blackburn-Munro RE (2005) Retigabine: chemical synthesis to clinical application. CNS Drug Rev 11:1-20.
3. Bunney BS, Walters JR, Roth RH, and Aghajanian GK (1973) Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185:560-571.
4. Cooper EC, Harrington E, Jan YN, and Jan LY (2001) M channel KCNQ2 subunits are localized to key sites for control of neuronal network oscillations and synchronization in mouse brain. J Neurosci 21:9529-9540.
5. Delmas P and Brown DA (2005) Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci 6:850-862.
6. Di Chiara G and Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
7. Di Giulio AM, Groppetti A, Cattabeni F, Galli CL, Maggi A, Algeri S, and Ponzio F (1978) Significance of dopamine metabolites in the evaluation of drugs acting on dopaminergic neurons. Eur J Pharmacol 52:201-207.
8. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, and Sibley DR (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science (Wash DC) 250:1429-1432.
9. Grace AA and Bunney BS (1980) Nigral dopamine neurons: intracellular recording and identification with L-dopa injection and histofluorescence. Science (Wash DC) 210:654-656.
10. Håkansson K, Pozzi L, Usiello A, Haycock J, Borrelli E, and Fisone G (2004) Regulation of striatal tyrosine hydroxylase phosphorylation by acute and chronic haloperidol. Eur J Neurosci 20:1108-1112.
11. Jentsch TJ (2000) Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 1:21-30.
12. Khan ZU, Mrzljak L, Gutierrez A, de la CA, and Goldman-Rakic PS (1998) Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci USA 95:7731-7736.
13. Kharkovets T, Hardelin JP, Safieddine S, Schweizer M, El-Amraoui A, Petit C, and Jentsch TJ (2000) KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci USA 97:4333-4338.
14. Korsgaard MP, Hartz BP, Brown WD, Ahring PK, Strobaek D, and Mirza NR (2005) Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J Pharmacol Exp Ther 314:282-292.
15. Koyama S and Appel SB (2006) Characterization of M-current in ventral tegmental area dopamine neurons. J Neurophysiol 96:535-543.
16. Kubisch C, Schroeder BC, Friedrich T, Lutjohann B, El Amraoui A, Marlin S, Petit C, and Jentsch TJ (1999) KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell 96:437-446.
17. Magnusson O, Mohringe B, and Fowler CJ (1987) Comparison of the effects of dopamine D1 and D2 receptor antagonists on rat striatal, limbic and nigral dopamine synthesis and utilisation. J Neural Transm 69:163-177.
18. Mikkelsen JD (2004) The KCNQ channel activator retigabine blocks haloperidol-induced c-Fos expression in the striatum of the rat. Neurosci Lett 362:240-243.
19. Mikkelsen JD, Vrang N, and Mrosovsky N (1998) Expression of Fos in the circadian system following nonphotic stimulation. Brain Res Bull 47:367-376.
20. Morgan JI and Curran T (1991) Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 14:421-451.
21. Nissbrandt H, Sundstrom E, Jonsson G, Hjorth S, and Carlsson A (1989) Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacts, pars reticulata, and striatum. J Neurochem 52:1170-1182.
22. Passmore GM, Selyanko AA, Mistry M, Al Qatari M, Marsh SJ, Matthews EA, Dickenson AH, Brown TA, Burbidge SA, Main M, et al. (2003) KCNQ/M currents in sensory neurons: significance for pain therapy. J Neurosci 23:7227-7236.
23. Paxinos G and Watson W(1986) The Rat Brain in Stereotaxic Coordinates, Academic Press, San Diego, CA.
24. Robertson GS and Fibiger HC (1992) Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46:315-328.
25. Robertson GS and Jian M (1995) D1 and D2 dopamine receptors differentially increase Fos-like immunoreactivity in accumbal projections to the ventral pallidum and midbrain. Neuroscience 64:1019-1034.
26. Robertson GS, Vincent SR, and Fibiger HC (1992) D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience 49:285-296.
27. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, Kutscher B, Loscher W, Honack D, White HS, et al. (1996) D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 23:211-223.
28. Salvatore MF, Garcia-Espana A, Goldstein M, Deutch AY, and Haycock JW (2000) Stoichiometry of tyrosine hydroxylase phosphorylation in the nigrostriatal and mesolimbic systems in vivo: effects of acute haloperidol and related compounds. J Neurochem 75:225-232.
29. Schmidt WJ, Schuster G, Wacker E, and Pergande G (1997) Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs. Eur J Pharmacol 327:1-9.
30. Seutin V, Scuvee-Moreau J, and Dresse A (1997) Evidence for a non-GABAergic action of quaternary salts of bicuculline on dopaminergic neurones. Neuropharmacology 36:1653-1657.
31. Seutin V, Scuvee-Moreau J, Giesbers I, Massotte L, and Dresse A (1990) Effect of BHT 920 on monoaminergic neurons of the rat brain: an electrophysiological in vivo and in vitro study. Naunyn-Schmiedeberg's Arch Pharmacol 342:502-507.
32. Shen W, Hamilton SE, Nathanson NM, and Surmeier DJ (2005) Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons. J Neurosci 25:7449-7458.
33. Shepard PD and Bunney BS (1991) Repetitive firing properties of putative dopamine-containing neurons in vitro: regulation by an apamin-sensitive Ca(2+)-activated K+ conductance. Exp Brain Res 86:141-150.
34. Swanson LW (1982) The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull 9:321-353.
35. Tatulian L, Delmas P, Abogadie FC, and Brown DA (2001) Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 21:5535-5545.
36. van Rijn CM and Willems-van Bree E (2003) Synergy between retigabine and GABA in modulating the convulsant site of the GABAA receptor complex. Eur J Pharmacol 464:95-100.
37. Weikop P, Kehr J, and Scheel-Kruger J (2004) The role of alpha1- and alpha2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. J Psychopharmacol 18:395-403.
38. Wolfart J, Neuhoff H, Franz O, and Roeper J (2001) Differential expression of the small-conductance, calcium-activated potassium channel SK3 is critical for pacemaker control in dopaminergic midbrain neurons. J Neurosci 21:3443-3456.
39. Yue C and Yaari Y (2004) KCNQ/M channels control spike afterdepolarization and burst generation in hippocampal neurons. J Neurosci 24:4614-4624.
40. Yus-Najera E, Munoz A, Salvador N, Jensen BS, Rasmussen HB, Defelipe J, and Villarroel A (2003) Localization of KCNQ5 in the normal and epileptic human temporal neocortex and hippocampal formation. Neuroscience 120:353-364.
41. Zetterström T, Sharp T, and Ungerstedt U (1986) Effect of dopamine D-1 and D-2 receptor selective drugs on dopamine release and metabolism in rat striatum in vivo. Naunyn-Schmiedeberg's Arch Pharmacol 334:117-124.